Brain Cancer

Early phase 2 data showed a median OS of 29.3 months with BPM31510 plus chemoradiation in an MGMT-unmethylated subgroup of treatment-naive glioblastoma.

In a phase 3 trial analysis, DCVax-L extended OS compared with individual patient data from external control populations in patients with glioblastoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Starting TTFields with chemoradiotherapy did not significantly improve OS vs using TTFields in the maintenance phase in newly diagnosed glioblastoma.

David Dinh Tran, MD, PhD, discusses the use of LITT followed by pembrolizumab in patients with recurrent high-grade astrocytoma.

Gabriel Zada, MD, discusses advanced surgical techniques for brain cancer in light of Brain Tumor Awareness Month.

The FDA has published new sets of product-specific guidelines for investigating generic cancer treatments to guide proper evaluation of bioequivalence.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Tovorafenib has received conditional marketing authorization in Europe for patients at least 6 months of age with BRAF-positive relapsed/refractory pLGG.

An NDA seeking the approval of TLX101-Px for characterizing treatment-related changes in recurrent or progressive glioma has been accepted by the FDA.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

Nogapendekin alfa inbakicept plus PD-L1 t-haNK and bevacizumab produced encouraging overall survival data in recurrent glioblastoma.

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses innovations in brain surgery and the importance of balancing oncological and functional outcomes.

Researchers at Northwestern Medicine have developed a new and faster approach to determine if a treatment for the brain cancer glioblastoma is working.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

Phase 1 data showed that LP-184 displayed an acceptable safety profile and was well-tolerated in heavily-pretreated patients with advanced solid tumors.

The first pediatric cancer progress report published by AACR identified strengths and weaknesses of contemporary pediatric cancer research.

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

IGV-001 produced an OS benefit vs placebo in newly diagnosed glioblastoma.

Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.